InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | 2026-03-09 | Raha Samraat S. | Director & President and CEO | Purchase | 40.0K | $5.00 | $200K | 493.1K | View ↗ | |
| 2026-02-27 | 2026-02-27 | Phanstiel S. Louise | Director | Purchase | 48.0K | $4.66 | $224K | 282.0K | View ↗ | |
| 2026-02-26 | 2026-02-27 | Phanstiel S. Louise | Director | Purchase | 50.4K | $4.80 | $242K | 234.0K | View ↗ | |
| 2026-02-25 | 2026-02-27 | Phanstiel S. Louise | Director | Purchase | 6,100 | $4.74 | $29K | 183.5K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $824.5M-1.6% | $837.6M+11.2% | $753.2M+11.0% | $678.4M-1.8% | $690.6M |
| Cost of revenue | $247.9M-1.7% | $252.2M+6.8% | $236.2M+16.9% | $202.0M+8.8% | $185.7M |
| Gross profit | $576.6M-1.5% | $585.4M+13.2% | $517.0M+8.5% | $476.4M | — |
| Research and development expense | $106.8M-5.8% | $113.4M+27.8% | $88.7M+3.9% | $85.4M+4.3% | $81.9M |
| Sales and marketing expense | $280.8M-1.2% | $284.1M-1.8% | $289.2M+8.4% | $266.8M | — |
| General and administrative expense | $256.8M-6.9% | $275.9M-2.7% | $283.7M+14.4% | $247.9M | — |
| Legal settlements | $0+100.0% | -$21.3M-118.9% | $112.8M | $0-100.0% | $62.0M |
| Goodwill and long-lived asset impairment charges | $319.4M+462.3% | $56.8M | $0-100.0% | $16.9M+838.9% | $1.8M |
| Total operating expenses | $963.8M+36.0% | $708.9M-8.5% | $774.4M+25.5% | $617.0M | — |
| Operating loss | -$387.2M-213.5% | -$123.5M+52.0% | -$257.4M-83.1% | -$140.6M+26.2% | -$190.5M |
| Interest income | $1.8M+5.9% | $1.7M-32.0% | $2.5M-3.8% | $2.6M+271.4% | $700K |
| Interest expense | -$10.5M-275.0% | -$2.8M+3.4% | -$2.9M+9.4% | -$3.2M+51.5% | -$6.6M |
| Other | $800K-27.3% | $1.1M+125.0% | -$4.4M-833.3% | $600K-99.6% | $139.3M |
| Total other expense | -$7.9M | $0+100.0% | -$4.8M | $0-100.0% | $133.4M |
| Loss before income tax | -$395.1M-219.9% | -$123.5M+52.9% | -$262.2M-86.5% | -$140.6M-146.2% | -$57.1M |
| Income tax (benefit) expense | -$29.2M-868.4% | $3.8M+245.5% | $1.1M+103.8% | -$28.6M+4.3% | -$29.9M |
| Net loss | -$365.9M-187.4% | -$127.3M+51.7% | -$263.3M-135.1% | -$112.0M-311.8% | -$27.2M |
| Basic (in dollars per share) | -$4.0M-180.1% | -$1.4M+55.7% | -$3.2M-128.8% | -$1.4M-297.1% | -$350K |
| Diluted (in dollars per share) | -$4.0M-180.1% | -$1.4M+55.7% | -$3.2M-128.8% | -$1.4M-297.1% | -$350K |
| Basic (in shares) | $92.6M+2.2% | $90.6M+9.4% | $82.8M+2.7% | $80.6M+3.3% | $78.0M |
| Diluted (in shares) | $92.6M+2.2% | $90.6M+9.4% | $82.8M+2.7% | $80.6M+3.3% | $78.0M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock
Myriad Genetics, Inc. 2026 Q1 - Results - Earnings Call Presentation
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences